Duaklir Genuair ইউরোপীয় ইউনিয়ন - এস্তোনীয় - EMA (European Medicines Agency)

duaklir genuair

covis pharma europe b.v. - aclidinium bromiid, formoterol dietüülfumaraat dihüdraat - kopsuhaigus, krooniline obstruktiivne - ravimid hingamisteede obstruktiivsete haiguste, - duaklir genuair on näidustatud bronhe lõõgastavaks säilitusraviks kroonilise obstruktiivse kopsuhaiguse (kok) täiskasvanud patsientidel sümptomite.

Trixeo Aerosphere ইউরোপীয় ইউনিয়ন - এস্তোনীয় - EMA (European Medicines Agency)

trixeo aerosphere

astrazeneca ab - formoterol fumarate dihydrate, glycopyrronium bromide, budesonide - kopsuhaigus, krooniline obstruktiivne - ravimid hingamisteede obstruktiivsete haiguste, - trixeo aerosphere is indicated as a maintenance treatment in adult patients with moderate to severe chronic obstructive pulmonary disease (copd) who are not adequately treated by a combination of an inhaled corticosteroid and a long acting beta2 agonist or combination of a long-acting beta2 agonist and a long acting muscarinic antagonist.

Riltrava Aerosphere ইউরোপীয় ইউনিয়ন - এস্তোনীয় - EMA (European Medicines Agency)

riltrava aerosphere

astrazeneca ab - budesonide, formoterol fumarate dihydrate, glycopyrronium bromide - kopsuhaigus, krooniline obstruktiivne - ravimid hingamisteede obstruktiivsete haiguste, - riltrava aerosphere is indicated as a maintenance treatment in adult patients with moderate to severe chronic obstructive pulmonary disease (copd) who are not adequately treated by a combination of an inhaled corticosteroid and a long-acting beta2 agonist or combination of a long-acting beta2 agonist and a long-acting muscarinic antagonist (for effects on symptoms control and prevention of exacerbations see section 5.

Bevespi Aerosphere ইউরোপীয় ইউনিয়ন - এস্তোনীয় - EMA (European Medicines Agency)

bevespi aerosphere

astrazeneca ab - glycopyrronium, formoterol fumarate dihydrate - kopsuhaigus, krooniline obstruktiivne - formoterol ja glycopyrronium bromiid - bevespi aerosphere on näidustatud hooldus bronchodilator ravi, et leevendada sümptomeid täiskasvanud patsientidel, kellel on krooniline obstruktiivne kopsuhaigus (copd).